Pipeline

Adamis Pharmaceuticals Product Pipeline

Specialty Pharmaceuticals

Adamis Laboratories’ Epinephrine Injection USP 1:1000 (0.3mg Pre-Filled Single Dose Syringe) (i.e.: Epinephrine Injection PFS) will compete as a “low cost, therapeutic alternative” to the well known brand EpiPen®. While an important piece of Adamis Labs’ product development strategy, Epinephrine Injection PFS serves as an introduction for the commercialization identity, and as a precursor, to the introduction of other revenue generating products.

Adamis Labs has identified several “niche” areas of respiratory medicine and its development pipeline includes an HFA inhaled nasal steroid for seasonal and perennial allergic rhinitis and two respiratory metered dose inhalers for asthma and COPD. Adamis intends to “carve out” commercialization for specific specialty prescribing audiences (e.g. allergists, pulmonologists, ENT’s) and partner with other pharma companies for the broader and valuable primary care audience.

Adamis Pharmaceuticals believes that the combination of specialty pharma and biotechnology can provide Adamis with the financial base of revenue and sufficient cash flow to help support development programs.

Biotechnology

Adamis technology combines and utilizes the scientific disciplines of immunology, molecular biology and gene therapy with the goal of producing novel vaccines for the potential treatment or prevention of various cancers and viral diseases. Adamis’ initial vaccine focus is on the treatment of prostate cancer. The same platform technology may also have the potential to be used for the treatment of other indications such as lung cancer, breast cancer and colon cancer. Future application for its platform vaccine technology include viral diseases such as chronic hepatitis and influenza. Adamis is also developing novel first-in-class compounds for the treatment of prostate cancer. Its first two compounds APC-100 and APC-200 won the NCI’s Rapid Award. The Rapid Award is given by the National Cancer Institute to what it believes are the most promising new drugs for the prevention and treatment of cancer. APC-100 is scheduled to enter a Phase 1 clinical study during 2011. APC-200 is in late pre-clinical testing and is anticipated to commence a Phase 1 clinical study in the first half of 2012. APC-300 is still in pre-clinical testing.